본문 바로가기
KERD
논문KCI 등재

Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma

성진실
연세대학교의과대학 (Yonsei University College of Medicine)|2009.10|Yonsei Medical Journal|제50권 제5호|pp. 601-612

1

조회

0

다운로드

7

인용

0

참고문헌

키워드

Radiotherapyhepatocellular carcinoma
주제분류의학일반

초록

Hepatocellular carcinoma (HCC) is one of the most critical global health issues. With frequent association of viral liver disease, HCC is highly complex, harboring both cancer and chronic liver disease. The tumor stage and underlying liver function are both major determinants of the treatment selection as well as prognosis in HCC patients, thus allowing no more than a 20% chance for potentially curative therapies. Radiotherapy technology has been evolved remarkably during the past decade, and radiation can be precisely delivered, thereby permitting higher doses to the tumour and reduced doses to surrounding normal tissues. There has been increasing interest in the merits of radiotherapy in HCC over the past few years, as indicated by a Pub Med search. Radiotherapy has been used as the definitive therapy with curative intent in early stage tumours. It has been used also in combination with TACE for intermediate stage tumours. In locally advanced tumours, radiotherapy has been combined with systemic agents. Despite its efficacy, radiotherapy has not yet been incorporated into the standard management guidelines of HCC. The lack of high evidence level data, especially randomized controlled trials, has posed an obstacle in including radiotherapy into the routine treatment schema of HCC. Therefore, well-designed prospective studies are strongly recommended using developing technology for radiotherapy alone or combination therapies. Also, many issues such as the optimal dose-fractionation, intra- or extrahepatic metastasis after radiotherapy, and radiation-induced hepatic dysfunction remain to be solved. In this review, current status of radiotherapy for HCC will be discussed with regard to technical consideration and combination strategy. The limitation and future perspectives will also be discussed.

Abstract

Hepatocellular carcinoma (HCC) is one of the most critical global health issues. With frequent association of viral liver disease, HCC is highly complex, harboring both cancer and chronic liver disease. The tumor stage and underlying liver function are both major determinants of the treatment selection as well as prognosis in HCC patients, thus allowing no more than a 20% chance for potentially curative therapies. Radiotherapy technology has been evolved remarkably during the past decade, and radiation can be precisely delivered, thereby permitting higher doses to the tumour and reduced doses to surrounding normal tissues. There has been increasing interest in the merits of radiotherapy in HCC over the past few years, as indicated by a Pub Med search. Radiotherapy has been used as the definitive therapy with curative intent in early stage tumours. It has been used also in combination with TACE for intermediate stage tumours. In locally advanced tumours, radiotherapy has been combined with systemic agents. Despite its efficacy, radiotherapy has not yet been incorporated into the standard management guidelines of HCC. The lack of high evidence level data, especially randomized controlled trials, has posed an obstacle in including radiotherapy into the routine treatment schema of HCC. Therefore, well-designed prospective studies are strongly recommended using developing technology for radiotherapy alone or combination therapies. Also, many issues such as the optimal dose-fractionation, intra- or extrahepatic metastasis after radiotherapy, and radiation-induced hepatic dysfunction remain to be solved. In this review, current status of radiotherapy for HCC will be discussed with regard to technical consideration and combination strategy. The limitation and future perspectives will also be discussed.

참고문헌 (86)

  1. Parkin DM, "Global cancer statistics, 2002", CA Cancer J Clin, 55, pp.74~108 (2005)
  2. Joo KR, "Hepatitis B viral markers of Korean adults in the late 1990s: survey data of 70,347 health screenees", Korean J Gastroenterol, 33, pp.642~652 (1999)
  3. Bosch FX, "Primary liver cancer: worldwide incidence and trends", Gastroenterology, 5, pp.S5~S16 (2004)
  4. Bruix J, "Clinical management of hepatocellular carcinoma, in Conclusions of the Barcelona-2000 EASL conference, in European Association for the Study of the Liver", J Hepatol, 35, pp.421~430 (2001)
  5. Bruix J, "Practice Guidelines Committee, American Association for the Study of Liver Diseases", Management of hepatocellular carcinoma. Hepatology, 42, pp.1208~1236 (2005)
  6. Llovet JM, "Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial", Lancet, 359, pp.1734~1739 (2002)
  7. Yuen MF, "Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B; results of a comparative study in 96 Chinese patients", Am J Gastroenterol, 98, pp.1181~1185 (2003)
  8. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
  9. Thomas M, "Molecular targeted therapy for hepatocellular carcinoma", J Gastroenterol, 44(19), pp.136~141 (2009)
  10. Ingold JA, "Radiation hepatitis", Am J Roentgenol Radium Ther Nucl Med, 93, pp.200~208 (1965)
  11. Lawrence TS, "Hepatic toxicity resulting from cancer treatment", Int J Radiat Oncol Biol Phys, 31, pp.1237~1248 (1995)
  12. Seong J, "Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 43, pp.393~397 (1999)
  13. Seong J, "Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization", Int J Radiat Oncol Biol Phys, 47, pp.1331~1335 (2000)
  14. Seong J, "Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients", Hepatol Res, 27, pp.30~35 (2003)
  15. Seong J, "Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients", Int J Radiat Oncol Biol Phys, 55, pp.329~336 (2003)
  16. Park W, "Local radiotherapy for patients with unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 61, pp.1143~1150 (2005)
  17. Cheng JC, "Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 47, pp.435~442 (2000)
  18. Dawson LA, "Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies", J Clin Oncol, 18, pp.2210~2218 (2000)
  19. Masuda T, "Intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy", J Hepatobiliary Pancreat Surg, 15, pp.589~595 (2008)
  20. Matsumoto Y, "Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance", J Hepatobiliary Pancreat Surg, 8, pp.435~440 (2001)
  21. Cochrane AM, "Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma", Cancer, 40, pp.609~614 (1977)
  22. Friedman MA, "Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study", Cancer Treat Rep, 63, pp.1885~1888 (1979)
  23. Stillwagon GB, "194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study", Int J Radiat Oncol Biol Phys, 17, pp.1223~1229 (1989)
  24. Park HC, "Dose-response relationship in local radiotherapy for hepatocellulcar carcinoma", Int J Radiat Oncol Biol Phys, 54, pp.150~155 (2002)
  25. Tai A, "Estimate of radiobiologic parameters from clinical data for biologically based treatment planning for liver irradiation", Int J Radiat Oncol Biol Phys, 70, pp.900~907 (2008)
  26. Withers HR, "Critical volume model", Int J Radiat Oncol Biol Phys, 25, pp.151~152 (1992)
  27. Niemierko A, "Modeling of normal tissue response to radiation: the critical volume model", Int J Radiat Oncol Biol Phys, 25, pp.135~145 (1993)
  28. Ben-Josef E, "Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies", J Clin Oncol, 23, pp.8739~8747 (2005)
  29. Seong J, "Lethal hepatic injury by combined treatment of radiation plus chemotherapy in rats with thioacetamide-induced liver cirrhosis", Int J Radiat Oncol Biol Phys, 57, pp.282~288 (2003)
  30. Rubin P, "Clinical radiation pathology, vol 1" (1968), WB Saunders
  31. Emami B, "Tolerance of normal tissue to therapeutic irradiation", Int J Radiat Oncol Biol Phys, 21, pp.109~122 (1991)
  32. Mornex F, "Feasibility and efficacy of high-dose three-dimensional conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies--mature results of the French Phase II RTF-1 trial", Int J Radiat Oncol Biol Phys, 66, pp.1152~1158 (2006)
  33. Lee IJ, "Radiotherapeutic parameters predictive of liver complications induced by liver tumor radiotherapy", Int J Radiat Oncol Biol Phys, 73, pp.154~158 (2009)
  34. Xu ZY, "Prediction of radiation-induced liver disease by Lyman normaltissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma", Int J Radiat Oncol Biol Phys, 65, pp.189~195 (2006)
  35. Cheng JC, "Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease", Int J Radiat Oncol Biol Phys, 60, pp.1502~1509 (2004)
  36. Dawson LA, "Analysis of radiation-induced liver disease using the Lyman NTCP model", Int J Radiat Oncol Biol Phys, 53, pp.810~821 (2002)
  37. Dawson LA, "Partial irradiation of the liver", Semin Radiat Oncol, 11, pp.240~246 (2001)
  38. Shirato H, "Realtime tumour-tracking radiotherapy", Lancet, 353, pp.1331~1332 (1999)
  39. Case RB, "Inter- and intrafraction variability in liver position in non-breathhold stereotactic body radiotherapy", Int J Radiat Oncol Biol Phys, 75, pp.302~308 (2009)
  40. Balter JM, "Daily targeting of intrahepatic tumors for radiotherapy", Int J Radiat Oncol Biol Phys, 52, pp.266~271 (2002)
  41. Jiang SB, "Radiotherapy of mobile tumors", Semin Radiat Oncol, 16, pp.239~248 (2006)
  42. Murphy MJ, "Tracking moving organs in real time", Semin Radiat Oncol, 14, pp.91~100 (2004)
  43. Dancey JE, "Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres", J Nucl Med, 41, pp.1673~1681 (2000)
  44. Geschwind JF, "Yttrium-90 microspheres for the treatment of hepatocellular carcinoma", Gastroenterology, 127, pp.S194~S205 (2004)
  45. Order S, "A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study", Int J Radiat Oncol Biol Phys, 20, pp.953~963 (1991)
  46. Raoul JL, "Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma", Hepatology, 26, pp.1156~1161 (1997)
  47. Kim JK, "Longterm clinical outcome of phase IIb clinical trial of percutaneous injection with holmium-166", chitosan complex (Milican) for the treatment of small hepatocellular carcinoma, 2006, pp.12, 543~548
  48. Sohn JH, "Phase II study of transarterial holmium-166-chitosan complex treatment in patients with a single, large hepatocellular carcinoma", Oncology, 76, pp.1~9 (2009)
  49. Ho S, "Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer", Eur J Nucl Med, 24, pp.293~298 (1997)
  50. Blomgren H, "Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients", Acta Oncol, 34, pp.861~867 (1995)
  51. Wulf J, "Stereotactic radiotherapy of primary liver cancer and hepatic metastases", Acta Oncol, 45, pp.838~847 (2006)
  52. Méndez Romero A, "Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study", Acta Oncol, 45, pp.831~837 (2006)
  53. Tse RV, "Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma", J Clin Oncol, 26, pp.657~664 (2008)
  54. Sakurai M, "Transcatheter chemoembolization effective for treating hepatocellular carcinoma, in A histopathologic study", Cancer, 54, pp.387~392 (1984)
  55. Yu YQ, "Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma", Cancer, 71, pp.62~65 (1993)
  56. Higuchi T, "Hepatocellular carcinoma after transcatheter hepatic arterial embolization, in A histopathologic study of 84 resected cases", Cancer, 73, pp.2259~2267 (1994)
  57. Baker DG, "The response of the microvascular system to radiation: a review", Cancer Invest, 7, pp.287~294 (1989)
  58. Byfield JE, "Cellular effects of combined adriamycin and x-irradiation in human tumor cells", Int J Cancer, 19, pp.194~204 (1977)
  59. Nakamura H, "Transcatheter oily chemoembolization of hepatocellular carcinoma", Radiology, 170, pp.783~786 (1989)
  60. Raoul JL, "Chemoembolization of hepatocellular carcinomas, in A Study of the biodistribution and pharmacokinetics of doxorubicin", Cancer, 70, pp.585~590 (1992)
  61. Shim SJ, "Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma", Liver Int, 25, pp.1189~1196 (2005)
  62. Yasuda S, "Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy", Int J Oncol, 15, pp.467~473 (1999)
  63. Guo WJ, "Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma", Br J Radiol, 73, pp.1091~1097 (2000)
  64. Chia-Hsien Cheng J, "Unresectable hepatocellular carcinoma treated with radiotherapy and", or chemoembolization, 2001, pp.96, 243~252
  65. Zeng ZC, "A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma", Cancer J, 10, pp.307~316 (2004)
  66. Meng MB, "Transcatheter arterial chemoembolization in combination with radiotherapy of unresectable hepatocellular carcinoma: a systematic review and meta-analysis", Radiother Oncol, 92, pp.184~194 (2009)
  67. Robertson JM, "Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy", J Clin Oncol, 11, pp.1286~1293 (1993)
  68. 김진석, "간문맥 혈전이 동반된 진행성 간세포암에서의 동시 항암 화학-방사선요법", The Korean Journal of Hepatology, 8(2002), pp.71~79 (2002), 대한간학회
  69. Han KH, "Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis", Cancer, 113, pp.995~1003 (2008)
  70. Tandon P, "Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies", Liver Int, 29, pp.502~510 (2009)
  71. Kim JK, "Prospective large scaled trial of concurrent intraarterial chemoradiation therapy following repeated intraarterial chemotherapy for advanced hepatocellular carcinoma with portal vein thrombosis", J Hepatol, 48, pp.S148~ (2008)
  72. Hsu WC, "Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma", Jpn J Clin Oncol, 36, pp.93~99 (2006)
  73. Zeng ZC, "A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and", or inferior vena cava tumor thrombus, 2005, pp.61, 432~443
  74. Nakagawa K, "Radiation therapy for portal venous invasion by hepatocellular carcinoma", World J Gastroenterol, 11, pp.7237~7241 (2005)
  75. 유찬란, "간문맥혈전을 동반한 거대 간세포암종 환자에서 간동맥항암 단독요법과 동시 방사선-간동맥항암 병합요법의 효과 비교", The Korean Journal of Hepatology, 13(3), pp.378~386 (2007), 대한간학회
  76. Kim TH, "Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable", Am J Clin Oncol, 29, pp.568~575 (2006)
  77. Kim DY, "Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma", Cancer, 103, pp.2419~2426 (2005)
  78. Kim JS, "Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis", Taehan Kan Hakhae Chi, 8, pp.71~79 (2002)
  79. Schulz-Ertner D, "Particle radiation therapy using proton and heavier ion beams", J Clin Oncol, 25, pp.953~964 (2007)
  80. Kawashima M, "Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma", J Clin Oncol, 23, pp.1839~1846 (2005)
  81. Kato H, "Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis", Int J Radiat Oncol Biol Phys, 59, pp.1468~1476 (2004)
  82. Seong J, "multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea", Liver Int, 29, pp.147~152 (2009)
  83. Cheng SH, "A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma", J Gastroenterol Hepatol, 14, pp.1025~1033 (1999)
  84. Han KH, "Treatment of non-resectable hepatocellular carcinoma", J Gastroenterol Hepatol, 17(3), pp.S424~S427 (2002)
  85. Cheng JC, "Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K", Akt, Oncogene, pp.2006, 25[DOI]
  86. Jiang Y, "Invasiveness of hepatocellular carcinoma cell lines: contribution of hepatocyte growth factor, c-met, and transcription factor Ets-1", Biochem Biophys Res Commun, 286, pp.1123~1130 (2001)

관련 논문AI추천

Strategic application of radiotherapy for hepatocellular carcinoma성진실, Seo Hee Choi대한간학회 · Clinical and Molecular Hepatology2018 · 제24권 제2호Current status of stereotactic body radiotherapy for the treatment of hepatocellular carcinoma강민규, 박재원, Jongmoo Park영남대학교 의과대학 · Journal of Yeungnam Medical Science2019 · 제36권 제3호The Optimal Selection of Radiotherapy Treatment for Hepatocellular Carcinoma성진실, 이익재거트앤리버 소화기연관학회협의회 · Gut and Liver2012 · 제6권 제2호Current role of proton beam therapy in patients with hepatocellular carcinomaGyu Sang Yoo, Hee Chul Park, Jeong Il Yu소화기인터벤션의학회 · International Journal of Gastrointestinal Intervention2021 · 제10권 제4호Current evidence and the potential role of proton beam therapy for hepatocellular carcinomaSung Uk Lee, Tae Hyun Kim대한간학회 · Clinical and Molecular Hepatology2023 · 제29권 제4호Treatment Outcomes of Helical Intensity-Modulated Radiotherapy for Unresectable Hepatocellular Carcinoma공문규, 김영경, 최우석, 최진현, 홍성언거트앤리버 소화기연관학회협의회 · Gut and Liver2013 · 제7권 제3호

이 간행물의 다른 논문 (12건)

A Survey of Pediatricians in Private Practices Who Participated in Community-Based Clerkships: An Intellectual, Inspirational and Professional Growth Experience김정수, Young Jon Kim, 주찬웅, 김선준pp. 613-616Relationship of Facet Tropism with Degeneration and Stability of Functional Spinal UnitYu-Duan Tsai, Wubing He, 공민호, Duc H. Do, Jeffrey C. Wang, Gun Keorochana, Nan-Fu Chenpp. 624-629Epidemiology and Control of an Outbreak of Vancomycin-Resistant Enterococci in the Intensive Care Units윤영경, 김정연, 이승은, 박대원, 노경호, 김민자, 손장욱, 심희선pp. 637-643Growth and Development of Infants with Asymptomatic Congenital Cytomegalovirus InfectionPing Fu, Xiaoliang Wang, Ruobing Shanpp. 667-671Severity Staging of Chronic Obstructive Pulmonary Disease: Differences in Pre- and Post-Bronchodilator SpirometryPan-Chyr Yang, Sow-Hsong Kuo, Ping-Hung Kuo, Sheng-Hsiang Linpp. 672-676
원문 보기